Sanofi Pasteur expands with plans for new quality-control building; AstraZeneca loses appeal in Germany over Seroquel generics;

@FiercePharma:  JPM: $GSK ready to shift off Advair; $TEVA CEO lists buyout reqs; $PFE building PCSK9 "franchise." Article | Follow @FiercePharma

@CarlyHFierce:  Big Pharma vs. 'growth pharma'? Let Actavis chief detail the differences. More | Follow @CarlyHFierce

> Sanofi Pasteur unveiled plans for a new, 27,000-square-foot quality-control building. Story

> AstraZeneca ($AZN) lost an appeal in Germany's Federal Court to block generic drugmakers from selling cheap copycats of its anti-psychotic drug Seroquel XR. More

> Doctors should question screening a wider group of patients for hepatitis C, even in light of new drugs that can cure the disease, according to a new study published in the British Medical Journal. Story

> Pfizer ($PFE) issued a letter to U.K. doctors warning them that even though its patent on anti-epilepsy drug pregabalin has expired, the company's patent on the med's use for pain treatment is still in effect until 2017. Item

@EmilyWFierce: Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. FiercePharmaMarketing story | Follow @EmilyWFierce

> Bard loses bid to delay vaginal mesh trial proceedings. Article

> DexCom: new CEO reports patient base grew by 50% in 2014. More

> Stakeholders look for clues to FDA's 2015 intentions regarding health IT. Story

Biotech News

@FierceBiotech: Intrexon and Ziopharm buy into CAR-T in $100M deal. Story | Follow @FierceBiotech

@JohnCFierce: First #FDA approved obesity device since 2007. More | Follow @JohnCFierce

> NeuroPhage wraps a $27M round to advance its Alzheimer's drug. Item

> Pfizer's cooking up a PCSK9-blocking pill. More

> Tobira eyes Wall Street with Regado merger, targeting NASH. More

Drug Delivery News

> Intersect ENT announces prelim Q4 financials at JPM, defining goals for its drug-loaded stents. More

> Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline. Story

> Pill-maker Capsugel collects Australian uni's tech for greater bioavailability. Article

> Extended-release drugs to face extra scrutiny from FDA's new Office of Pharmaceutical Quality. Item

> Alnylam and Isis strengthen RNAi alliance, agree to swap IP. More

Diagnostics News

> Roche snatches up majority share in Foundation Medicine for $1B plus milestones. News

> Biocept joins up with Insight Genetics for lung cancer test. Report

> Qiagen acquires Enzymatics, gains NGS partner ArcherDX. Story

> Biodesix ropes in $12M in Series E financing for blood-based lung cancer Dx. More

> Qiagen exceeds 2014 placement goals for molecular Dx, hedges its bets on continued success. Article

Pharma Marketing News

> Shire CEO sees 'home turf' marketing advantage with NPS buy. Report

> Actavis CEO: We may be big, but we don't want to be Big Pharma. News

> Some ad types are calling it: 'Pharmageddon' is over. DTC is back. Article

> Turning drug adherence into a game actually works, study finds. Report

> Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. More

And Finally… Pharma execs are staying optimistic about business in 2015, according to a new survey, with more than half of individuals saying that conditions will be better for their companies in the coming year. More

Suggested Articles

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.